Update on asthma step-therapy

Allergy and Asthma Proceedings

Volumn 31, Issue 6, 2010, Pages 444-451

  Dinakar, Chitra ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; FORMOTEROL FUMARATE; MONTELUKAST; PLACEBO; PREDNISONE; SALBUTAMOL; SALMETEROL; STEROID; THEOPHYLLINE;

ADD ON THERAPY; ASTHMA; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HUMAN; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ASTHMA; CHILD; CLINICAL PROTOCOLS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; EXPERT TESTIMONY; HUMANS; LEUKOTRIENES; PRACTICE GUIDELINES AS TOPIC; THEOPHYLLINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78650483349     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2010.31.3395     Document Type: Review

References (41)

1. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma - Summary Report 2007. J Allergy Clin Immunol 120(5 Suppl):S94-S138, 2007.
2. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: Athma control and exacerbations: Standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 180:59-99, 2009.
3. Chapman KR. SMART isn't. J Allergy Clin Immunol 125:609-610, 2008.
4. Szefler SJ, Gergen PJ, Mitchell H, and Morgan W. Achieving asthma control in the inner city: Do the National Institutes of Health Asthma Guidelines really work? J Allergy Clin Immunol 125:521-526; quiz 527-528, 2010.
5. Fitzgerald JM and Shahidi N. Achieving asthma control in patients with moderate disease. J Allergy Clin Immunol 125:307-311, 2010.
6. Ducharme F, Schwartz Z, Hicks G, and Kakuma R. Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev (2):CD003133, 2004.
7. Barnes PJ, Pedersen S, and Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 157:S1-S53, 1998. (Pubitemid 28125600)
8. Adams N, Bestall J, and Jones P. Inhaled beclomethasone at different doses for long-term asthma. Cochrane Database Syst Rev (1):CD002879, 2001.
9. Adams N, Bestall J, and Jones PW. Budesonide at different doses for chronic asthma. Cochrane Database Syst Rev (4):CD003271, 2001.
10. Adams NP, Bestall JC, Jones P, et al. Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev (4):CD003534, 2008.
11. Ni Chroinin M, Greenstone T, Lasserson TJ, and Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev (4):CD005307, 2009.
12. Ni Chroinin M, Greenstone IR, Danish A, et al. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev (4):CD005535, 2005.
13. Ducharme FM, Lasserson TJ, and Cates CJ. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev (4):CD003137, 2006.
14. Evans DJ, Taylor DA, Zetterstrom O, et al. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 337: 1412-1418, 1997. (Pubitemid 27497888)
15. Yurdakul AS, Calisir HC, Tunctan B, and Ogretensoy M. Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma. Respir Med 96:322-329, 2002.
16. Irvin CG, Kaminski DA, Anthonisen NR, et al. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respire Crit Care Med. 175:235-242, 2007.
17. Chowdhury BA and Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 362:1169-1171, 2010.
18. Castle W, Fuller R, Hall J, and Palmer J. Serevent nationwide surveillance study: Comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Brit Med J 306:1034-1037, 1993. (Pubitemid 23105961)
19. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129:15-26, 2006.
20. Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 124:70-74, 2003. (Pubitemid 36851333)
21. Bensch G, Berger WE, Blokhin BM, et al. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol 89:180-190, 2002.
22. Salpeter SR, Buckley NS, Ormiston TM, and Salpeter EE. Meta-analysis: Effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144: 904-912, 2006.
23. Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: Effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 149:33-42, 2008.
24. Jaeschke R, O'Byrne PM, Mejza F, et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: Systematic review and meta-analysis. Am J Respir Crit Care Med 178:1009-1016, 2008.
25. Sears MR. Safety of long-acting beta-agonists: Are new data really required? Chest 136:604-607, 2009.
26. Wijesinghe M, Weatherall M, Perrin K, et al. Risk of mortality associated with formoterol: A systematic review and meta-analysis. Eur Respir J 34:803-811, 2009.
27. Nelson H, Bonuccelli C, Radner F, et al. Safety of formoterol in patients with asthma: Combined analysis of data from double-blind, randomized controlled trials. J Allergy Clin Immunol. 125:390-396, e8, 2010.
28. Kelly MM, O'Connor TM, Leigh R, et al. Effects of budesonide and formoterol on allergen-induced airway responses, inflammation, and airway remodeling in asthma. J Allergy Clin Immunol. 125:349-356, e13, 2010.
29. Kazani S and Israel E. Long-acting beta-agonists and inhaled corticosteroids: Is the whole greater than the sum of its parts? J Allergy Clin Immunol. 125:357-358, 2010.
30. Bateman ED, Reddel HK, Eriksson G, et al. Overall asthma control: The relationship between current control and future risk. J Allergy Clin Immunol. 125:600-608, 2010.
31. Cates CJ and Lasserson TJ. Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev 2:CD007313, 2009.
32. Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 362:975-985, 2010.
33. Hagiwara M, Delea TE, Stanford RH, and Stempel DA. Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapy. Allergy Asthma Proc 31:203-210, 2010.
34. Fuhlbrigge AL, Weiss ST, Kuntz KM, and Paltiel AD. Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma. Pediatrics 118:e347-e355, 2006.
35. Ulrik CS and Frederiksen J. Mortality and markers of risk of asthma death among 1,075 outpatients with asthma. Chest 108:10-15, 1995.
36. van Rensen EL, Sont JK, Evertse CE, et al. Bronchial CD8 cell infiltrate and lung function decline in asthma. Am J Respir Crit Care Med 172:837-841, 2005.
37. Tantisira KG, Fuhlbrigge AL, Tonascia J, et al. Bronchodilation and bronchoconstriction: Predictors of future lung function in childhood asthma. J Allergy Clin Immunol 117:1264-1271, 2006. (Pubitemid 43795734)
38. Sont JK, Willems LN, Bel EH, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 159: 1043-1051, 1999.
39. Nuijsink M, Hop WC, Sterk PJ, et al. Long-term asthma treatment guided by airway hyperresponsiveness in children: A randomised controlled trial. Eur Respir J 30:457-466, 2007.
40. Doull J, Sandall D, Smith S, et al. Differential inhibitory effect of regular inhaled corticosteroid on airway responsiveness to adenosine 5′ monophosphate, methacholine, and bradykinin in symptomatic children with recurrent wheeze. Pediatr Pulmonol 23:404-411, 1997.
41. van den Berge M, Kerstjens HA, Meijer RJ, et al. Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med 164:1127-1132, 2001.